Identification

Name
Sufentanil
Accession Number
DB00708  (APRD00671, DB05563)
Type
Small Molecule
Groups
Approved, Investigational
Description

An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. [PubChem]

Structure
Thumb
Synonyms
  • N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide
  • N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide
  • Sufentanil
  • Sufentanilo
  • Sufentanilum
  • Sufentanyl
External IDs
IDS-NS-001 / R 30730 / R 33800
Product Ingredients
IngredientUNIICASInChI Key
Sufentanil CitrateS9ZFX8403R60561-17-3OJCZPLDERGDQRJ-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sufenta Inj 50mcg/mlLiquid50 mcgEpidural; IntravenousJanssen Pharmaceuticals1985-12-312007-11-26Canada
Sufenta Inj 50mcg/mlLiquid50 mcgIntravenousJanssen Pharmaceutica, Division Of Janssen Ortho Inc.1985-12-311996-09-10Canada
Sufentanil CitrateInjection50 ug/mLEpidural; IntravenousAkorn2010-12-01Not applicableUs
Sufentanil Citrate Injection USPSolution50 mcgEpidural; IntravenousSandoz Canada Incorporated2001-08-01Not applicableCanada
Sufentanil Citrate Injection, USPSolution50 mcgEpidural; IntravenousSterimax Inc2016-10-18Not applicableCanada
ZalvisoTablet15 μgSublingualGrunenthal Gmb H2015-09-18Not applicableEu
ZalvisoTablet15 μgSublingualGrunenthal Gmb H2015-09-18Not applicableEu
ZalvisoTablet15 μgSublingualGrunenthal Gmb H2015-09-18Not applicableEu
ZalvisoTablet15 μgSublingualGrunenthal Gmb H2015-09-18Not applicableEu
ZalvisoTablet15 μgSublingualGrunenthal Gmb H2015-09-18Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sufentanil CitrateInjection, solution50 ug/mLEpidural; IntravenousHospira, Inc.1996-12-11Not applicableUs
Sufentanil CitrateInjection.05 mg/mLEpidural; IntravenousWest Ward Pharmaceutical1995-12-15Not applicableUs
Sufentanil CitrateInjection, solution50 ug/mLEpidural; IntravenousHospira, Inc.1996-12-11Not applicableUs
Sufentanil CitrateInjection.05 mg/mLEpidural; IntravenousWest Ward Pharmaceutical1995-12-15Not applicableUs
Sufentanil CitrateInjection.05 mg/mLEpidural; IntravenousWest Ward Pharmaceutical1995-12-15Not applicableUs
International/Other Brands
Chronogesic (DURECT) / Disufen (Angenerico) / Fastfen (Cristália) / Sufenta (Janssen) / Sufenta Forte (Janssen) / Sufenta mite (Janssen) / Sufentil (Claris Lifesciences Ltd.) / Zuftil (Pisa)
Categories
UNII
AFE2YW0IIZ
CAS number
56030-54-7
Weight
Average: 386.551
Monoisotopic: 386.202798904
Chemical Formula
C22H30N2O2S
InChI Key
GGCSSNBKKAUURC-UHFFFAOYSA-N
InChI
InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3
IUPAC Name
N-[4-(methoxymethyl)-1-[2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropanamide
SMILES
CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1

Pharmacology

Indication

Used as an analgesic adjunct in anesthesia and as a primary anesthetic drug in procedures requiring assisted ventilation and in the relief of pain.

Structured Indications
Not Available
Pharmacodynamics

Sufentanil is a synthetic opioid analgesic. Sufentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Sufentanil may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Sufentanil depresses the respiratory centers, depresses the cough reflex, and constricts the pupils.

Mechanism of action

Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Sufentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids open calcium-dependent inwardly rectifying potassium channels (OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

TargetActionsOrganism
AMu-type opioid receptor
agonist
Human
UDelta-type opioid receptor
agonist
Human
UKappa-type opioid receptor
other
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

265 minutes

Clearance
Not Available
Toxicity

LD50: 18.7 mg/kg (IV in mice)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Sufentanil Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Sufentanil.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Sufentanil.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Sufentanil.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Sufentanil is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineSufentanil may increase the serotonergic activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcebutololSufentanil may increase the bradycardic activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Sufentanil.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Sufentanil is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Agomelatine.Approved, Investigational
AlaproclateSufentanil may increase the serotonergic activities of Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Sufentanil.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Alfentanil.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Sufentanil.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Sufentanil is combined with Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sufentanil.Approved, Illicit, Investigational
AlprenololSufentanil may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AlvimopanThe risk or severity of adverse effects can be increased when Sufentanil is combined with Alvimopan.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Sufentanil.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amiloride.Approved
AmiodaroneThe metabolism of Sufentanil can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amlodipine.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Sufentanil which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Sufentanil.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Sufentanil.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amyl Nitrite.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Sufentanil.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Sufentanil.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Sufentanil can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Sufentanil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sufentanil.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sufentanil.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Asenapine.Approved
AtazanavirThe metabolism of Sufentanil can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the bradycardic activities of Sufentanil.Approved
AtomoxetineThe metabolism of Sufentanil can be decreased when combined with Atomoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Sufentanil.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Sufentanil.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Sufentanil.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Azaperone.Investigational, Vet Approved
AzelastineSufentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Azilsartan medoxomil.Approved
AzosemideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Sufentanil is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Sufentanil.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Sufentanil.Approved
BefunololSufentanil may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Sufentanil.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bendroflumethiazide.Approved
BenmoxinSufentanil may increase the serotonergic activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Sufentanil.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Sufentanil.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Sufentanil is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Sufentanil.Approved, Withdrawn
BeractantSufentanil may increase the bradycardic activities of Beractant.Approved
BetaxololBetaxolol may increase the bradycardic activities of Sufentanil.Approved
BevantololSufentanil may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Sufentanil.Approved, Investigational
BisoprololBisoprolol may increase the bradycardic activities of Sufentanil.Approved
BL-1020BL-1020 may increase the hypotensive activities of Sufentanil.Investigational
BoceprevirThe metabolism of Sufentanil can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololSufentanil may increase the bradycardic activities of Bopindolol.Approved
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Sufentanil.Experimental
BortezomibThe metabolism of Sufentanil can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Sufentanil can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Sufentanil.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sufentanil.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololSufentanil may increase the bradycardic activities of Bucindolol.Investigational
BufuralolSufentanil may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bupivacaine.Approved, Investigational
BupranololSufentanil may increase the bradycardic activities of Bupranolol.Approved
BuprenorphineSufentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Sufentanil.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sufentanil.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Sufentanil is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Sufentanil.Approved, Illicit, Vet Approved
CalfactantSufentanil may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Candesartan cilexetil.Approved
CanertinibThe risk or severity of adverse effects can be increased when Sufentanil is combined with Canertinib.Investigational
Canrenoic acidThe risk or severity of adverse effects can be increased when Sufentanil is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Canrenone.Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Captopril.Approved
CarbamazepineThe metabolism of Sufentanil can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Sufentanil.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Carisoprodol.Approved
CaroxazoneSufentanil may increase the serotonergic activities of Caroxazone.Withdrawn
CarteololCarteolol may increase the bradycardic activities of Sufentanil.Approved
CarvedilolSufentanil may increase the bradycardic activities of Carvedilol.Approved, Investigational
CeliprololSufentanil may increase the bradycardic activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Sufentanil can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sufentanil.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Sufentanil.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Sufentanil.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Sufentanil.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sufentanil.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Sufentanil.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cinchocaine.Approved, Vet Approved
CitalopramSufentanil may increase the serotonergic activities of Citalopram.Approved
ClarithromycinThe metabolism of Sufentanil can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Sufentanil can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Sufentanil.Approved, Investigational
ClofenamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clofenamide.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when Sufentanil is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clonazepam.Approved, Illicit
ClonidineClonidine may increase the bradycardic activities of Sufentanil.Approved
ClopamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clopamide.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clopenthixol.Experimental
CloranololSufentanil may increase the bradycardic activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sufentanil.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clorexolone.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Sufentanil can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Sufentanil.Approved
CobicistatThe metabolism of Sufentanil can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Sufentanil.Approved, Illicit
ConivaptanThe serum concentration of Sufentanil can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Sufentanil can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclobenzaprine.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Sufentanil.Approved
CyclosporineThe metabolism of Sufentanil can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Sufentanil can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dapiprazole.Approved
DapoxetineSufentanil may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Sufentanil.Approved, Investigational
DarunavirThe metabolism of Sufentanil can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Sufentanil can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Sufentanil can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Sufentanil can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desmopressin.Approved
DesvenlafaxineSufentanil may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Sufentanil.Withdrawn
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Sufentanil.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Sufentanil.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Diazepam.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Diclofenamide.Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Sufentanil.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Sufentanil is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of Sufentanil.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Difenoxin.Approved, Illicit
DigoxinDigoxin may increase the bradycardic activities of Sufentanil.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Sufentanil can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Sufentanil can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dinutuximab.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dipyridamole.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dixyrazine.Experimental
DonepezilSufentanil may increase the bradycardic activities of Donepezil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Doxepin.Approved
DoxycyclineThe metabolism of Sufentanil can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Sufentanil is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Illicit
DronedaroneThe metabolism of Sufentanil can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Drotebanol.Experimental, Illicit
DuloxetineSufentanil may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Sufentanil is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Efonidipine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Eltanolone.Investigational
EluxadolineSufentanil may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Sufentanil.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sufentanil.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Sufentanil is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Sufentanil can be decreased when it is combined with Enzalutamide.Approved
EpanololSufentanil may increase the bradycardic activities of Epanolol.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Sufentanil.Approved
EprosartanThe risk or severity of adverse effects can be increased when Sufentanil is combined with Eprosartan.Approved
ErythromycinThe metabolism of Sufentanil can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramSufentanil may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmololEsmolol may increase the bradycardic activities of Sufentanil.Approved
EstazolamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sufentanil.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etacrynic acid.Approved
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Sufentanil.Experimental
EthanolSufentanil may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Sufentanil.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etomidate.Approved
EtoperidoneSufentanil may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Sufentanil.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Sufentanil.Approved
FenquizoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fenquizone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Sufentanil.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Sufentanil.Approved, Investigational
FingolimodSufentanil may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Sufentanil can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flunitrazepam.Approved, Illicit
FluoxetineSufentanil may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sufentanil.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sufentanil.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Sufentanil can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Sufentanil can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Sufentanil can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Sufentanil can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fospropofol.Approved, Illicit, Investigational
FurazolidoneSufentanil may increase the serotonergic activities of Furazolidone.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Sufentanil can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Gabapentin Enacarbil.Approved
GalantamineGalantamine may increase the bradycardic activities of Sufentanil.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Sufentanil.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Sufentanil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Sufentanil is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepefrineGepefrine may increase the analgesic activities of Sufentanil.Experimental
GepironeThe risk or severity of adverse effects can be increased when Sufentanil is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Sufentanil.Approved, Investigational, Vet Approved
GuanfacineSufentanil may increase the bradycardic activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sufentanil.Approved
HalothaneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Sufentanil.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Sufentanil.Approved
HydracarbazineSufentanil may increase the serotonergic activities of Hydracarbazine.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneSufentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sufentanil.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of Sufentanil.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Sufentanil.Approved
IbopamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ibopamine.Experimental
IdelalisibThe serum concentration of Sufentanil can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Sufentanil.Approved, Investigational
ImatinibThe metabolism of Sufentanil can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Sufentanil.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Imipramine.Approved
IndalpineSufentanil may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Indapamide.Approved
IndenololSufentanil may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe metabolism of Sufentanil can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Sufentanil is combined with Indiplon.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Sufentanil.Withdrawn
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of Sufentanil.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Sufentanil.Approved
IproclozideSufentanil may increase the serotonergic activities of Iproclozide.Withdrawn
IproniazidSufentanil may increase the serotonergic activities of Iproniazid.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Sufentanil is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Sufentanil can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sufentanil.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Isoflurane.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Isosorbide.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Sufentanil can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Sufentanil can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineSufentanil may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Sufentanil can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Sufentanil can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the bradycardic activities of Sufentanil.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Sufentanil.Approved, Investigational
LacosamideSufentanil may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lamotrigine.Approved, Investigational
LandiololSufentanil may increase the bradycardic activities of Landiolol.Investigational
LanreotideSufentanil may increase the bradycardic activities of Lanreotide.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Sufentanil.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levetiracetam.Approved, Investigational
LevobunololSufentanil may increase the bradycardic activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levocetirizine.Approved
LevodopaSufentanil may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranSufentanil may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Sufentanil.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Sufentanil.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Sufentanil.Approved, Investigational
LopinavirThe metabolism of Sufentanil can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sufentanil.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lormetazepam.Approved
LosartanThe risk or severity of adverse effects can be increased when Sufentanil is combined with Losartan.Approved
LovastatinThe metabolism of Sufentanil can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Sufentanil.Approved
LucinactantSufentanil may increase the bradycardic activities of Lucinactant.Approved, Investigational
LuliconazoleThe serum concentration of Sufentanil can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Sufentanil can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Maprotiline.Approved
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Sufentanil.Experimental
MebanazineSufentanil may increase the serotonergic activities of Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mebicar.Experimental
MebutizideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Sufentanil.Approved
MeclizineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Medetomidine.Vet Approved
MefrusideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mefruside.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Sufentanil is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Melperone.Approved, Investigational
MephedroneMephedrone may increase the analgesic activities of Sufentanil.Investigational
MephentermineMephentermine may increase the analgesic activities of Sufentanil.Approved
MepindololSufentanil may increase the bradycardic activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sufentanil.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Meptazinol.Experimental
MersalylThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Sufentanil.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Sufentanil.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Sufentanil.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Sufentanil.Approved
MethotrimeprazineSufentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of Sufentanil.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methyclothiazide.Approved
MethyldopaSufentanil may increase the bradycardic activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methylecgonine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Sufentanil.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methylphenobarbital.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Sufentanil.Approved
MeticraneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Meticrane.Experimental
MetipranololSufentanil may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Sufentanil.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Metolazone.Approved
MetoprololMetoprolol may increase the bradycardic activities of Sufentanil.Approved, Investigational
MetyrosineSufentanil may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Sufentanil.Approved, Illicit
MidomafetamineMidomafetamine may increase the analgesic activities of Sufentanil.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Sufentanil can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranSufentanil may increase the serotonergic activities of Milnacipran.Approved
MinaprineSufentanil may increase the serotonergic activities of Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Minoxidil.Approved
MirtazapineSufentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Sufentanil can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Sufentanil.Experimental, Illicit
MoclobemideSufentanil may increase the serotonergic activities of Moclobemide.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Sufentanil.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Sufentanil.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Sufentanil.Approved, Investigational
MuzolimineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Investigational
NadololSufentanil may increase the bradycardic activities of Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nalbuphine.Approved
NaltrexoneThe therapeutic efficacy of Sufentanil can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NebivololSufentanil may increase the bradycardic activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Sufentanil can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Sufentanil can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Sufentanil can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Sufentanil can be increased when combined with Nevirapine.Approved
NialamideSufentanil may increase the serotonergic activities of Nialamide.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Sufentanil.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nifedipine.Approved
NilotinibThe metabolism of Sufentanil can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Sufentanil.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sufentanil.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sufentanil.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Sufentanil.Approved
OctamoxinSufentanil may increase the serotonergic activities of Octamoxin.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Sufentanil.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sufentanil.Approved, Investigational
OlaparibThe metabolism of Sufentanil can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Sufentanil is combined with Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Sufentanil is combined with Opium.Approved, Illicit
OrphenadrineSufentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Sufentanil is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Sufentanil can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Sufentanil.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxethazaine.Approved, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Sufentanil.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Sufentanil.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sufentanil.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Sufentanil.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sufentanil.Approved, Vet Approved
PalbociclibThe serum concentration of Sufentanil can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Paliperidone.Approved
PamabromThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pamabrom.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Sufentanil.Approved
PapaverineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Papaverine.Approved
ParaldehydeSufentanil may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineSufentanil may increase the serotonergic activities of Pargyline.Approved
ParoxetineSufentanil may increase the serotonergic activities of Paroxetine.Approved, Investigational
PasireotideSufentanil may increase the bradycardic activities of Pasireotide.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Sufentanil.Approved
PenbutololSufentanil may increase the bradycardic activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sufentanil.Approved, Vet Approved
PentobarbitalThe metabolism of Sufentanil can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Sufentanil.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved
PerazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Sufentanil is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Sufentanil.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sufentanil.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Sufentanil.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Sufentanil is combined with Phenibut.Experimental
PheniprazineSufentanil may increase the serotonergic activities of Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Sufentanil can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Sufentanil.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Phenoxyethanol.Approved
PhenoxypropazineSufentanil may increase the serotonergic activities of Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Sufentanil.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Sufentanil.Approved
PhenytoinThe metabolism of Sufentanil can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pimozide.Approved
PindololSufentanil may increase the bradycardic activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Sufentanil.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pipotiazine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Sufentanil.Approved
PiretanideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Piritramide.Investigational
PirlindoleSufentanil may increase the serotonergic activities of Pirlindole.Approved
PivhydrazineSufentanil may increase the serotonergic activities of Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pizotifen.Approved
Platelet Activating FactorSufentanil may increase the bradycardic activities of Platelet Activating Factor.Experimental
PolythiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pomalidomide.Approved
Poractant alfaSufentanil may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Sufentanil can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium Citrate.Approved, Vet Approved
PractololSufentanil may increase the bradycardic activities of Practolol.Approved
PramipexoleSufentanil may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sufentanil.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Prilocaine.Approved
PrimidoneThe metabolism of Sufentanil can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sufentanil.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Sufentanil.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Sufentanil.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Promethazine.Approved
PropafenoneSufentanil may increase the bradycardic activities of Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Sufentanil is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Sufentanil.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Proparacaine.Approved, Vet Approved
PropericiazinePropericiazine may increase the hypotensive activities of Sufentanil.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Sufentanil.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Sufentanil.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Propoxycaine.Approved
PropranololPropranolol may increase the bradycardic activities of Sufentanil.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Sufentanil is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Sufentanil.Approved
QuazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quinapril.Approved, Investigational
QuinethazoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Sufentanil.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ramipril.Approved
RamosetronSufentanil may increase the constipating activities of Ramosetron.Approved, Investigational
RanolazineThe metabolism of Sufentanil can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sufentanil.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Sufentanil.Approved, Investigational
RifabutinThe metabolism of Sufentanil can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Sufentanil can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Sufentanil can be increased when combined with Rifapentine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Sufentanil is combined with Riociguat.Approved
RisperidoneSufentanil may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Sufentanil.Investigational
RivastigmineSufentanil may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Romifidine.Vet Approved
RopiniroleSufentanil may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ropivacaine.Approved
RotigotineSufentanil may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Sufentanil.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Sufentanil.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Sufentanil.Approved
SafrazineSufentanil may increase the serotonergic activities of Safrazine.Withdrawn
SaquinavirThe metabolism of Sufentanil can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Sufentanil.Approved, Vet Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sufentanil.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Sufentanil.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sufentanil is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineSufentanil may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Sufentanil can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Sufentanil can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Sufentanil can be increased when it is combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Sufentanil.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Sufentanil.Approved
SotalolSotalol may increase the bradycardic activities of Sufentanil.Approved
SpiradolineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Spiradoline.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Sufentanil can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Sufentanil can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Sufentanil.Approved, Investigational
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Sufentanil.Approved
SulfisoxazoleThe metabolism of Sufentanil can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Sultopride.Experimental
SuvorexantSufentanil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TalinololSufentanil may increase the bradycardic activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Sufentanil can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Sufentanil can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Sufentanil is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Sufentanil.Approved
TerazosinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Terazosin.Approved
TertatololSufentanil may increase the bradycardic activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrodotoxin.Investigational
ThalidomideSufentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Theobromine.Approved, Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Sufentanil.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Sufentanil.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Thiopental.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Sufentanil.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sufentanil.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Sufentanil can be decreased when combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tilidine.Experimental
TimololTimolol may increase the bradycardic activities of Sufentanil.Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Sufentanil.Approved
TizanidineTizanidine may increase the bradycardic activities of Sufentanil.Approved
TocilizumabThe serum concentration of Sufentanil can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Sufentanil.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tolcapone.Approved, Withdrawn
ToloxatoneSufentanil may increase the serotonergic activities of Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Sufentanil.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Sufentanil.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Sufentanil.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Sufentanil.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triprolidine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Sufentanil.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Sufentanil.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Sufentanil.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Sufentanil.Approved
UlaritideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Sufentanil.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Sufentanil is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Sufentanil is combined with Valsartan.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Sufentanil.Approved
VenlafaxineThe metabolism of Sufentanil can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Veralipride.Experimental
VerapamilThe metabolism of Sufentanil can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Sufentanil is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Sufentanil can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Sufentanil is combined with Xenon.Experimental
XipamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ziconotide.Approved
ZimelidineSufentanil may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Sufentanil can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zolazepam.Vet Approved
ZolpidemSufentanil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Jacob Mathew, J. Killgore, "New methods for the synthesis of alfentanil, sufentanil, and remifentanil." U.S. Patent US20060149071, issued July 06, 2006.

US20060149071
General References
Not Available
External Links
Human Metabolome Database
HMDB14846
KEGG Drug
D05938
KEGG Compound
C08022
PubChem Compound
41693
PubChem Substance
46504737
ChemSpider
38043
BindingDB
94503
ChEBI
9316
ChEMBL
CHEMBL658
Therapeutic Targets Database
DAP000357
PharmGKB
PA451527
IUPHAR
3534
Guide to Pharmacology
GtP Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Sufentanil
ATC Codes
N01AH03 — Sufentanil
AHFS Codes
  • 28:08.08 — Opiate Agonists
MSDS
Download (47.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic SciencePlasma Concentrations1
1, 2TerminatedTreatmentOpioids / Pain1
2CompletedTreatmentAnaesthesia therapy1
2CompletedTreatmentMajor Upper or Lower Abdominal Surgery1
2CompletedTreatmentPain1
2CompletedTreatmentPregnant Women1
2Not Yet RecruitingTreatmentHead Trauma1
2RecruitingTreatmentPrenatal Diagnosis1
2WithdrawnTreatmentPain, Chronic1
2, 3Active Not RecruitingTreatmentCerebral Hypoperfusion / Intubation, Endotracheal / Premedication1
2, 3Active Not RecruitingTreatmentIntubation, Endotracheal / Premedication1
2, 3CompletedSupportive CareHealthy Volunteers / Pelvic Floor Disorders / Prolonged Labour1
2, 3RecruitingTreatmentMyocardial Injury1
3CompletedPreventionNormal Pregnancies1
3CompletedTreatmentChild Comfort / Intensive Care Units / Morphine / Pediatric1
3CompletedTreatmentModerate-to-severe Acute Pain1
3CompletedTreatmentPain, Acute1
3CompletedTreatmentPost Operative Pain1
3CompletedTreatmentPost-Operative Pain3
3CompletedTreatmentPostoperative pain1
3Not Yet RecruitingTreatmentObstetric Pain / Other Complications of Obstetric Anesthesia - Delivered1
3RecruitingTreatmentLumbar epidural anesthesia therapy1
4Active Not RecruitingTreatmentDriving Performance After Minor Ambulatory Surgery / Minor Surgical Procedures With Monitored Anesthesia Care1
4CompletedNot AvailableAortic Aneurysms1
4CompletedBasic ScienceAnaesthesia therapy1
4CompletedPreventionAortic Valve Stenosis / Ischaemic Heart Diseases1
4CompletedSupportive CarePain1
4CompletedSupportive CarePostoperative pain / Prophylaxis against postoperative nausea and vomiting1
4CompletedTreatmentAnalgesics / Pain, Chronic / Postoperative pain1
4CompletedTreatmentPain3
4CompletedTreatmentPostoperative pain2
4CompletedTreatmentSingle Traumatic Limb Injury With Severe Pain (Score > 5/10 on Numerical Pain Scale)1
4Enrolling by InvitationSupportive CarePostoperative; Dysfunction Following Cardiac Surgery1
4Not Yet RecruitingPreventionPostoperative Cognitive Dysfunction / Postoperative Delirium1
4Not Yet RecruitingTreatmentAnalgesia, Patient-Controlled / Anesthesia; Spinal / Intravenous Drug Delivery Systems / Lumbar epidural anesthesia / Morphine / Surgery, Colorectal1
4RecruitingPreventionCoronary Artery Bypass Graft Redo / General Anesthetic Drug Adverse Reaction1
4RecruitingSupportive CarePregnancy1
4RecruitingTreatmentArteriovenous Malformations1
4RecruitingTreatmentLabour Pain1
4RecruitingTreatmentNumeric Pain Rating Scale > 5 / 10 / Severe Traumatic Pain1
4RecruitingTreatmentPain, Acute1
4RecruitingTreatmentPatients Ongoing Elective Abdominal Laparoscopy1
4RecruitingTreatmentPostoperative pain1
4TerminatedTreatmentAnalgesia / Sedation therapy1
4TerminatedTreatmentThoracic Surgery1
4Unknown StatusTreatmentAdrenal Suppression / Hemodynamics Instability1
4Unknown StatusTreatmentAnalgesia, Patient-Controlled / Arthroplasty / Gastric Resection1
Not AvailableCompletedNot AvailableAdequate Anesthesia With Unimpaired Motor Strength1
Not AvailableCompletedDiagnosticProstate Cancer1
Not AvailableCompletedOtherLoss of Consciousness1
Not AvailableCompletedPreventionAnaesthesia therapy / Pain1
Not AvailableCompletedPreventionKidney Donation/Transplantation1
Not AvailableCompletedSupportive CareEpidural Block / Malignant Neoplasm of Esophagus / Oesophagectomy1
Not AvailableCompletedSupportive CareInstrumental Delivery / Lumbar epidural anesthesia / Maternal Outcome / Neonatal Outcome1
Not AvailableCompletedSupportive CareTotal Knee Arthroplasty (TKA)1
Not AvailableCompletedTreatmentAnaesthesia therapy1
Not AvailableCompletedTreatmentAnesthesia Complications1
Not AvailableCompletedTreatmentBalanced Anesthesia1
Not AvailableCompletedTreatmentIschaemic Heart Diseases1
Not AvailableCompletedTreatmentLabour Pain1
Not AvailableCompletedTreatmentNeoplasms, Pancreatic1
Not AvailableCompletedTreatmentPediatric Ventricular Septal Defects1
Not AvailableCompletedTreatmentPost Operative Pain Management1
Not AvailableNot Yet RecruitingSupportive CareCardiovascular Disease (CVD)1
Not AvailableNot Yet RecruitingTreatmentC.Delivery; Surgery (Previous), Gynecological1
Not AvailableNot Yet RecruitingTreatmentLiver Diseases / Neoplasms, Hepatic / Secondary Malignant Neoplasm of Liver1
Not AvailableNot Yet RecruitingTreatmentPostoperative Complications1
Not AvailableRecruitingPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableRecruitingTreatmentLabor Analgesia1
Not AvailableRecruitingTreatmentLabour Pain1
Not AvailableTerminatedDiagnosticLabour Pain1
Not AvailableUnknown StatusHealth Services ResearchPregnancy1
Not AvailableUnknown StatusSupportive CareAdjunct to general anesthesia therapy1
Not AvailableUnknown StatusTreatmentHaemodynamic Fluctuations During Off-pump CABG1

Pharmacoeconomics

Manufacturers
  • Akorn inc
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
LiquidEpidural; Intravenous50 mcg
LiquidIntravenous50 mcg
InjectionEpidural; Intravenous.05 mg/mL
InjectionEpidural; Intravenous50 ug/mL
Injection, solutionEpidural; Intravenous50 ug/mL
SolutionEpidural; Intravenous50 mcg
TabletSublingual15 μg
Prices
Unit descriptionCostUnit
Sufentanil citrate powder18927.0USD g
Sufenta 50 mcg/ml ampul5.38USD ml
Sufentanil 50 mcg/ml ampul3.92USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)97 °CPhysProp
water solubility76 mg/L (at 25 °C)ROY,SD & FLYNN,GL (1988)
logP3.95SANGSTER (1993)
logS-3.71ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.012 mg/mLALOGPS
logP3.4ALOGPS
logP3.61ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)8.86ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area32.78 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity111.42 m3·mol-1ChemAxon
Polarizability43.85 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9875
Blood Brain Barrier+0.9886
Caco-2 permeable+0.5201
P-glycoprotein substrateSubstrate0.6673
P-glycoprotein inhibitor IInhibitor0.8275
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterNon-inhibitor0.5594
CYP450 2C9 substrateNon-substrate0.7923
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.713
CYP450 1A2 substrateNon-inhibitor0.8954
CYP450 2C9 inhibitorNon-inhibitor0.7839
CYP450 2D6 inhibitorNon-inhibitor0.8416
CYP450 2C19 inhibitorNon-inhibitor0.5438
CYP450 3A4 inhibitorInhibitor0.6293
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6401
Ames testNon AMES toxic0.7695
CarcinogenicityNon-carcinogens0.8861
BiodegradationNot ready biodegradable0.9724
Rat acute toxicity3.0968 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9793
hERG inhibition (predictor II)Inhibitor0.772
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0009000000-0f9e477eb2153eb20409
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0096000000-73641c83c08b872641cd
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-06ri-1981000000-b5f4aaab095cc6fc533c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-1900000000-2fdfd1d5fa6e43fa1604
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-4900000000-bd92c052347dc0822a01

Taxonomy

Description
This compound belongs to the class of organic compounds known as anilides. These are organic heterocyclic compounds derived from oxoacids RkE(=O)l(OH)m (l not 0) by replacing an OH group by the NHPh group or derivative formed by ring substitution.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Anilides
Alternative Parents
Aralkylamines / Piperidines / Thiophenes / Tertiary carboxylic acid amides / Heteroaromatic compounds / Trialkylamines / Amino acids and derivatives / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
Anilide / Aralkylamine / Piperidine / Tertiary carboxylic acid amide / Heteroaromatic compound / Thiophene / Amino acid or derivatives / Carboxamide group / Tertiary amine / Tertiary aliphatic amine
show 15 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
piperidines, thiophenes, ether, anilide (CHEBI:9316)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Hurle MA: Changes in the expression of G protein-coupled receptor kinases and beta-arrestin 2 in rat brain during opioid tolerance and supersensitivity. J Neurochem. 2001 Apr;77(2):486-92. [PubMed:11299311]
  2. Levron JC: [Pharmacokinetics and pharmacodynamics of morphinomimetics in the central nervous system]. Agressologie. 1991;32(6-7):318-20. [PubMed:1688220]
  3. Ilien B, Galzi JL, Mejean A, Goeldner M, Hirth C: A mu-opioid receptor-filter assay. Rapid estimation of binding affinity of ligands and reversibility of long-lasting ligand-receptor complexes. Biochem Pharmacol. 1988 Oct 15;37(20):3843-51. [PubMed:2847746]
  4. Colpaert FC, Leysen JE, Michiels M, van den Hoogen RH: Epidural and intravenous sufentanil in the rat: analgesia, opiate receptor binding, and drug concentrations in plasma and brain. Anesthesiology. 1986 Jul;65(1):41-9. [PubMed:3014923]
  5. Leysen JE, Gommeren W: In vitro binding properties of 3H-sufentanil, a superior ligand for the mu-opiate receptor. Arch Int Pharmacodyn Ther. 1982 Dec;260(2):287-9. [PubMed:6131653]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Freye E, Latasch L, Portoghese PS: The delta receptor is involved in sufentanil-induced respiratory depression--opioid subreceptors mediate different effects. Eur J Anaesthesiol. 1992 Nov;9(6):457-62. [PubMed:1330549]
  2. Zhu J, Xue JC, Law PY, Claude PA, Luo LY, Yin J, Chen C, Liu-Chen LY: The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor. FEBS Lett. 1996 Apr 15;384(2):198-202. [PubMed:8612823]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Zhu J, Xue JC, Law PY, Claude PA, Luo LY, Yin J, Chen C, Liu-Chen LY: The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor. FEBS Lett. 1996 Apr 15;384(2):198-202. [PubMed:8612823]
  2. Chang HM, Berde CB, Holz GG 4th, Steward GF, Kream RM: Sufentanil, morphine, met-enkephalin, and kappa-agonist (U-50,488H) inhibit substance P release from primary sensory neurons: a model for presynaptic spinal opioid actions. Anesthesiology. 1989 Apr;70(4):672-7. [PubMed:2467589]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34